Stock Ratings / Health Care / PCVX / financials

KRYS (72) KYMR (50) QGEN (71) IBRX (37) ⌘ Pro Terminal →

Vaxcyte Inc. (PCVX) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$62.03 -0.93% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $61.81

Vaxcyte Inc. (PCVX) carries a Roarable Rating of D (Sell) with 49/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (49/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $9.85B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PCVX Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is PCVX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Vaxcyte Inc. (NASDAQ: PCVX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 49/100 at a spot price of $62.03 (-0.93% 1D, market cap $9.85B). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 6/20. Across 1016 tracked Health Care issuers, PCVX ranks #303 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does PCVX compare to KRYS and KYMR in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), PCVX carries a Roarable D (49/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -27.6%. By comparison, KRYS (Krystal Biotech Inc.) holds a B grade (72/100 RQD, P/E 46.9x, ROIC 16.5%, cap $9.61B) and KYMR (Kymera Therapeutics Inc.) posts a D grade (50/100 RQD, P/E 32.7x, ROIC -21.4%, cap $10.19B). Among the 5-stock peer group, QGEN leads on earnings multiple (24.4x) while KRYS leads on capital efficiency (16.5% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PCVX?

▼

Per PCVX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001649094), Vaxcyte Inc. generated $0 in revenue, -$766.6K in net income, and -$669.3M in free cash flow against $3.00B in total assets and $142.7M in total debt. Key quantitative strengths: Clean SEC annual filing review with no major hidden accounting time-bombs.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $61.81 (-0.36%)🧬 Dilution Drag (+1.64% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (49/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.4% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE-4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PCVX)Realized 20D OHLCV Swing Band: ±10.7%

Deterministic 5-Pillar Attribution (49/100 Composite)

🔍 WHY PCVX SCORES 49/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (33% of score)

Altman Z-Score 18.11 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▲ #2 Bullish Driver: Whale & Options Positioning+12/20 pts (24% of score)

20D Institutional Volume Accumulation (±10.7% realized swing band)

▼ #1 Drag / Risk Factor: Cash Engine Quality5/20 pts (-15 pt drag)

Capital intensity & 0% operating margin leave 15 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C$66.80-0.9% Next Q

Q2 (-2Q)

Grade C-$66.23-8.4% Next Q

Q3 (-1Q)

Grade C-$60.67+2.2% Next Q

Current

Grade D$62.03-5.4% Hist 90D α

Trajectory: C (57) → D (49)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a PCVX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While PCVX currently carries a cautious 49/100 (D) rating due to Cash Engine Quality (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Clean SEC annual filing review with no major hidden accounting time-bombs.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($61.62) and Max Pain ($65.13) forces dealer call-delta covering toward $95.29.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.64% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PCVX• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “PCVX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 49%NO 51%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How PCVX Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $4.00B

FY24

Rev $4.00B

FY25

Rev $4.00B

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$4.00B	0%	-23.1%	-$766.6K	-$669.3M	-27.5%
FY 2024	$4.00B	0%	-14.2%	-$463.9K	-$475.1M	-14.9%
FY 2023	$4.00B	0%	-11.7%	-$402.3K	-$296.8M	-11.3%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PCVX)

✓Walkthrough of PCVX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

PCVX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +6.05%▲ ASCENDING CHANNEL

2026-11-02O $61.46H $62.61L $61.46C $62.03VOL 2.01M

RES: $100.4SUP: $56.91SMA50: $61.62SMA200: $57.19

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PCVX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PCVX Butterfly Map → + Track PCVX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

16.8%/yr Implied 5Y Growth

vs. +19.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on PCVX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PCVX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for PCVX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PCVX)

Health Care Rank #303 of 1016 ⚔️ KRYS vs PCVX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PCVX vs. KRYS, KYMR, QGEN, IBRX)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Vaxcyte Inc. (PCVX) ranks #303 by composite RQD confidence (49/100, grade D) and #115 by equity capitalization ($9.85B). Within this direct 5-issuer industry benchmark cohort, QGEN leads on earnings valuation at 24.4x trailing P/E, while KRYS leads on capital efficiency and profitability with 16.5% ROIC and — gross margin. KRYS currently holds the highest overall quantitative score in the immediate peer group at 72/100 (B) compared with PCVX at 49/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
PCVX ACTIVE Vaxcyte Inc.	D	49/100	—	—	-27.6%	-0.93%	$9.85B	Benchmark Subject
KRYS Krystal Biotech Inc.	B	72/100	46.9x	—	16.5%	+2.38%	$9.61B	/krys-vs-pcvx →
KYMR Kymera Therapeutics Inc.	D	50/100	32.7x	—	-21.4%	+3.29%	$10.19B	/kymr-vs-pcvx →
QGEN Qiagen N.V.	B-	71/100	24.4x	62.2%	8.0%	-0.24%	$10.37B	/qgen-vs-pcvx →
IBRX ImmunityBio Inc.	D-	37/100	—	96.0%	-27.3%	-5.15%	$9.26B	/ibrx-vs-pcvx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001649094

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Vaxcyte Inc. (PCVX) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$766.6K, operating cash flow of -$655.6M, and free cash flow of -$669.3M (-40.9% YoY). On the balance sheet, PCVX closed FY2025 with $3.00B in total assets against $142.7M in total debt (Altman Z-Score: 18.11, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$766.6K	-$655.6M	-$669.3M	$3.00B	$142.7M
FY2024 (FY)	2024-12-31	$0	-$463.9K	-$452.6M	-$475.1M	$3.51B	$92.5M
FY2023 (FY)	2023-12-31	$0	-$402.3K	-$296.8M	-$296.8M	$5.42B	$1.27B

3. PCVX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PCVX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does PCVX compare to KRYS and KYMR in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for PCVX?

Where is PCVX trading relative to its 50-day, 200-day, and 52-week technical levels?

PCVX last traded at $62.03 (-0.93% on volume of 1,714,650 shares), positioning the stock +0.67% above its 50-day simple moving average ($61.62) and +8.46% above its 200-day simple moving average ($57.19). Across its 52-week range of $39.87 to $90.75, PCVX sits at the 43.6% percentile with a 14-day RSI of 50.1 (NEUTRAL RANGE) and an implied next-earnings move of ±10.7% ($55.39 to $68.67).

PCVX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is Vaxcyte Inc. (PCVX)?

In FY 2025 (10-K), PCVX converted $4.0B of revenue into a 0% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Direct Sub-Reports: PCVX RQD Cockpit PCVX 12M Forecast PCVX Earnings & Move PCVX Dividends & DRIP PCVX Insiders & 13F PCVX Whale Options PCVX Profit Sankey PCVX News & Why

ROARABLE RATING BRIEF • RQD 49/100 (D) ✓ STAGE-C NUMBER FIREWALL VERIFIED

PCVX — Vaxcyte Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:16:46Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, PCVX scores 49 out of 100, a letter grade of D, with the verdict "Roarable Sell — Underperform / Distribution Warning." Across the five pillars, the Fundamental Cash Engine scores 5 of 20 (ROIC -27.6%; FCF yield -6.79%), indicating the weakest contribution to the score. Whale/13F Flow scores 12 of 20 (institutional accumulation and options positioning), Insider Conviction scores 6 of 20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit scores 10 of 20 (Beta 1.07; sector sensitivity), and Forensic Balance Sheet scores 16 of 20 (Altman Z 18.11; Piotroski F 4/9; Debt/Equity 0.05).

For a prospective investor, the pattern is that the balance sheet is the strongest pillar while the cash-generation and insider-conviction pillars are weak. Negative ROIC and negative FCF yield mean the business is not currently converting capital into cash returns, so any upside case depends on future catalysts rather than present earnings power. The positive institutional and options signal offsets part of the weakness but does not change the overall distribution-warning verdict. Valuation tradeoffs are visible in the forward P/E of 23 alongside zero trailing EPS, meaning the price relies on expectations not yet reflected in reported earnings.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$0.0M	$-923.7M	$-0.8M	N/A	$-669.3M	$174.0M	$142.7M
FY 2024	$0.0M	$-569.5M	$-0.5M	N/A	$-475.1M	$387.9M	$92.5M
FY 2023	$0.0M	$-468.0M	$-0.4M	N/A	$-296.8M	N/A	$1268.2M

Per the SEC financials, the company reported no revenue across the three periods and operating losses that widened from $-468.0M in FY 2023 to $-923.7M in FY 2025. Per the market data, operating margin is -33.5%, gross margin and net margin are 0%, and ROIC is -27.6%. Per the Roarable RQD rating, the Altman Z-Score is 18.11, the Piotroski F-Score is 4/9, and Debt/Equity is 0.05, indicating a balance sheet with low leverage despite negative operating cash flow.

Recent Catalysts & News Wire Analysis

Per the recent news feed, the most prominent headline reports the closing of a $1.15 Billion public offering of common stock, pre-funded warrants, and convertible senior notes, including full exercise of underwriters' options. Per the same feed, Guggenheim raised its price target following a vaccine trial win (flagged GREEN), and the stock was reported to hit a new 52-week high. Other items include Investor's Business Daily coverage comparing the company to Pfizer and Merck in a $7 Billion market, and a Seeking Alpha note titled "Vaccine Titan In The Making."

Risk watch items: the $1.15 Billion financing is a dilution and capital-raise event relevant to the negative FCF and the $-669.3M FY 2025 free cash flow. Per the Butterfly Supply-Chain Graph, there are no proprietary signals.

Open Questions

What are the company's commercial products, revenue model, and any timeline to revenue, given zero reported revenue across all periods?
What are the terms and dilution impact of the $1.15 Billion offering, including convertible note conversion prices?
What is the clinical and regulatory pipeline status behind the reported vaccine trial win?
Why does the source show FY 2023 cash as N/A while reporting $1268.2M in debt, and how does that reconcile with the balance sheet trend?
What is the basis for the reported trailing EPS of 0 alongside negative net income?

PCVX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Vaxcyte Inc. (PCVX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to PCVX Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 7h ago

Vaxcyte Announces Closing of $1.15 Billion Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes, Including Full Exercise of Underwriters’ Options to Purchase Additional Shares and Convertible Senior Notes

Yahoo Finance report covering Vaxcyte Inc. (PCVX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investor's Business Daily • 10h ago

Small Biotech Squares Up To Pfizer, Merck In $7 Billion Market

Investor's Business Daily report covering Vaxcyte Inc. (PCVX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Investing.com • 13h ago

Guggenheim raises Vaxcyte stock price target on vaccine trial win

Investing.com report covering Vaxcyte Inc. (PCVX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingKey • 16h ago

Vaxcyte Inc Stock (PCVX) Moved Up by 9.47% on Oct 9: What Signal Does It Send?

TradingKey report covering Vaxcyte Inc. (PCVX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 19h ago

Vaxcyte Stock Hits New 52-Week High - Here’s Why

Benzinga report covering Vaxcyte Inc. (PCVX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Seeking Alpha • 22h ago

Vaxcyte: Vaccine Titan In The Making (NASDAQ:PCVX)

Seeking Alpha report covering Vaxcyte Inc. (PCVX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Yahoo Finance • 1d ago

Why Vaxcyte (PCVX) Is Getting Attention Again

Yahoo Finance report covering Vaxcyte Inc. (PCVX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Investing.com • 1d ago

Vaxcyte stock soars 50% on positive phase 3 vaccine data

Investing.com report covering Vaxcyte Inc. (PCVX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

PCVX Bull vs. Bear Conversation Board — What's Your Call at $62.03?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PCVX 🐻 50% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $67.62 (+8.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is PCVX (D • RQD 49/100) a Buy at $62.61?

Welcome to the PCVX (Vaxcyte Inc.) Roar Pit. Current RQD Composite is 49/100 (Roarable Sell — Underperform / Distribution Warning) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

VA ValDiscipline Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $51.34 (-18.0%)

Spot @ $62.61

Pump the brakes on PCVX — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on PCVX, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Vaxcyte Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MI MidwestValue Verified K Arena Trader 🐂 BULLISH 🎯 Target: $72.63 (+16.0%)

Spot @ $62.61

PCVX cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on PCVX, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $62.61 (52-wk range $39.87 - $90.75), any beat on forward guidance forces shorts and underweight funds to chase.